کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2093899 1081985 2015 11 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease
ترجمه فارسی عنوان
سلول های بنیادی مزانشیمال و سرولاکسین با همکاری فیبروز فیبروسیون فیبروسیس را در یک مدل آزمایشگاهی بیماری مزمن آلرژیک هوایی
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی بیوتکنولوژی یا زیست‌فناوری
چکیده انگلیسی


• MSCs alone demonstrated modest anti-fibrotic effects in an experimental model of chronic allergic airway disease in vivo.
• In combination with the anti-fibrotic, serelaxin, MSCs completely abrogated airway/lung fibrosis.
• The TGF-β1-inhibitory effects of serelaxin were found to complement the gelatinase-promoting effects of MSCs.
• This combination therapy also reduced airway inflammation to a greater extent than either therapy alone.

This study determined if the anti-fibrotic drug, serelaxin (RLN), could augment human bone marrow-derived mesenchymal stem cell (MSC)-mediated reversal of airway remodeling and airway hyperresponsiveness (AHR) associated with chronic allergic airways disease (AAD/asthma). Female Balb/c mice subjected to the 9-week model of ovalbumin (OVA)-induced chronic AAD were either untreated or treated with MSCs alone, RLN alone or both combined from weeks 9–11. Changes in airway inflammation (AI), epithelial thickness, goblet cell metaplasia, transforming growth factor (TGF)-β1 expression, myofibroblast differentiation, subepithelial and total lung collagen deposition, matrix metalloproteinase (MMP) expression, and AHR were then assessed. MSCs alone modestly reversed OVA-induced subepithelial and total collagen deposition, and increased MMP-9 levels above that induced by OVA alone (all p < 0.05 vs OVA group). RLN alone more broadly reversed OVA-induced epithelial thickening, TGF-β1 expression, myofibroblast differentiation, airway fibrosis and AHR (all p < 0.05 vs OVA group). Combination treatment further reversed OVA-induced AI and airway/lung fibrosis compared to either treatment alone (all p < 0.05 vs either treatment alone), and further increased MMP-9 levels. RLN appeared to enhance the therapeutic effects of MSCs in a chronic disease setting; most likely a consequence of the ability of RLN to limit TGF-β1-induced matrix synthesis complemented by the MMP-promoting effects of MSCs.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Stem Cell Research - Volume 15, Issue 3, November 2015, Pages 495–505
نویسندگان
, , , , , ,